Gilead Sciences’ seladelpar has been recommended by the European Medicines Agency’s human medicines committee to treat the ...

Is your medical education strategy reaching the right HCPs in the formats they prefer? Discover actionable insights to ...

Elevate your MedEd strategy with our 2025 toolkit! From AI-driven patient avatars to interactive augmented reality scenarios, ...

AstraZeneca’s Tagrisso (osimertinib) has been approved by the European Commission (EC) to treat a new subset of lung cancer ...

We live in a hyper-connected world. This has clear benefits for the health of our communities, our businesses and our planet. But are those connections working for or against your… ...

Merck & Co – known as MSD outside the US and Canada – will be gaining exclusive global rights to Hansoh Pharma’s preclinical GLP-1 candidate in a deal worth over $2bn. The agreement gives Merck a ...

Sanofi’s investigational Bruton’s tyrosine kinase (BTK) inhibitor tolebrutinib has been granted breakthrough therapy designation by the US Food and Drug Administration (FDA) as a treatment for adults ...

Established in 2006 by a group of highly experienced outsourcing business specialists, Apodi provides comprehensive outsourcing solutions to pharmaceutical and healthcare businesses and organisations.

Novo Nordisk has announced an investment of 8.5 billion Danish kroner, or approximately $1.2bn, to establish a new rare disease production facility in Odense, Denmark. Construction on the new site, ...

In theory, the principles of omnichannel – personalised content through the right channels to maximise customer experience – are applicable to rare diseases. In practice though, going ‘full throttle’ ...

Sanofi has announced plans to invest approximately €1bn to build a new insulin production base in China. The site, located in the Beijing Economic and Technological Development Zone, will be aimed at ...